Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICM-926
- Development stage
- Preclinical
- Lead developer
- ICM Research
- Modality
- Small Molecules
01
Overview
ICM-926 is an investigational small molecule therapeutic being developed by ICM Therapeutics for the treatment of Polycystic Kidney Disease (PKD) and Polycystic Liver Disease (PLD). As of early 2024, the drug is in the preclinical stage of development, having completed animal studies with IND-enabling activities pending. While the specific molecular target of ICM-926 has not been publicly disclosed, the developer, ICM Therapeutics, focuses on mitochondrial medicine and the development of new chemical entities (NCEs) to treat chronic and infectious diseases. The program aims to address the significant unmet medical need for the millions of patients worldwide affected by cyst growth in the kidneys and liver.
Beyond the preview
Go deeper on ICM-926.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICM-926.